CSIMarket
 


Cassava Sciences Inc  (SAVA)
Other Ticker:  
 
 

SAVA's Capital Expenditures Growth by Quarter and Year

Cassava Sciences Inc's Capital Expenditures results by quarter and year




SAVA Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.04 2.71 0.10 0.00
III Quarter September 0.37 0.00 22.04 0.00
II Quarter June 0.00 0.00 0.07 0.00
I Quarter March 0.36 0.43 0.00 0.00
FY   0.77 3.14 22.21 0.00



SAVA Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Cassava Sciences Inc reported drop in Capital Expenditures in the fourth quarter 2023 by -98.49% to $ 0.04 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Cassava Sciences Inc's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 4458.43%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Capital Expenditures growth. While Cassava Sciences Inc' s Capital Expenditures meltdown of -98.49% ranks overall at the positon no. 1827 in the fourth quarter 2023.




SAVA Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -98.49 % 2610 % - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March -16.28 % - - -
FY   -75.45 % -85.86 % - -

Financial Statements
Cassava Sciences Inc's fourth quarter 2023 Capital Expenditures $ 0.04 millions SAVA's Income Statement
Cassava Sciences Inc's fourth quarter 2022 Capital Expenditures $ 2.71 millions Quarterly SAVA's Income Statement
New: More SAVA's historic Capital Expenditures Growth >>


SAVA Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -88.92 % - -99.55 % -
III Quarter September - - 31385.71 % -
II Quarter June - - - -
I Quarter March -86.72 % 330 % - -
FY (Year on Year)   -75.45 % -85.86 % - -




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #242
Overall #1827

Capital Expenditures Y/Y Growth Statistics
High Average Low
30093.15 % 4458.43 % -100 %
(Sep 30 2021)   (Jun 30 2023)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #242
Overall #1827
Capital Expenditures Y/Y Growth Statistics
High Average Low
30093.15 % 4458.43 % -100 %
(Sep 30 2021)   (Jun 30 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cassava Sciences Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
30093.15 % 4458.43 % -100 %
(Sep 30 2021)  


SAVA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Cassava Sciences Inc reported fall in Capital Expenditures from the third quarter by -88.92% to $ 0.04 millions, from $ 0.37 millions declared a quarter before.

Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cassava Sciences Inc's Capital Expenditures growth quarter on quarter, overall rank is 1827.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #242
Overall #1827
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #242
Overall #1827
Capital Expenditures Q/Q Growth Statistics
High Average Low
30093.15 % 4458.43 % -100 %
(Sep 30 2021)  


SAVA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Cassava Sciences Inc reported fall in Capital Expenditures sequentially by -88.92% to $ 0.04 millions, from $ 0.37 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cassava Sciences Inc's Capital Expenditures growth quarter on quarter, overall rank is 1827.


Cassava Sciences Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Cassava Sciences Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Cassava Sciences Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Cassava Sciences Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Cassava Sciences Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
SAVA's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for SAVA's Competitors
Capital Expenditures Growth for Cassava Sciences Inc's Suppliers
Capital Expenditures Growth for SAVA's Customers

You may also want to know
SAVA's Annual Growth Rates SAVA's Profitability Ratios SAVA's Asset Turnover Ratio SAVA's Dividend Growth
SAVA's Roe SAVA's Valuation Ratios SAVA's Financial Strength Ratios SAVA's Dividend Payout Ratio
SAVA's Roa SAVA's Inventory Turnover Ratio SAVA's Growth Rates SAVA's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com